Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to -$19.9 million.

  • Gyre Therapeutics' Cash from Investing Activities rose 47.76% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.3 million, marking a year-over-year increase of 73.85%. This contributed to the annual value of -$19.9 million for FY2024, which is 0.63% down from last year.
  • Gyre Therapeutics' Cash from Investing Activities amounted to -$19.9 million in FY2024, which was down 0.63% from -$19.8 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Cash from Investing Activities ranged from a high of $48.2 million in FY2021 and a low of -$19.9 million during FY2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$19.8 million (2023), whereas its average is -$17.8 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Cash from Investing Activities skyrocketed by 398.70% in 2021, and later tumbled by 128.67% in 2022.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Cash from Investing Activities stood at $9.7 million in 2020, then spiked by 398.70% to $48.2 million in 2021, then crashed by 128.67% to -$13.8 million in 2022, then crashed by 43.04% to -$19.8 million in 2023, then fell by 0.63% to -$19.9 million in 2024.